{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:40:02Z","timestamp":1679233202877},"reference-count":53,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Compar. Effect. Res."],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:p>Drug-eluting stents have dramatically reduced the risk of restenosis, but concerns of an increased risk of stent thrombosis have provided uncertainty about their use. Recent studies have continued to show improved procedural and clinical outcomes with drug-eluting stents both in the setting of acute coronary syndromes and stable coronary artery disease. Newer generation drug-eluting stents (especially everolimus-eluting stents) have been shown to be not only efficacious but also safe with reduced risk of stent thrombosis when compared with bare-metal stents, potentially changing the benchmark for stent safety from bare-metal stents to everolimus-eluting stents. While much progress is being made in the development of bioabsorbable polymer stents, nonpolymer stents and bioabsorbable stent technology, it remains to be seen whether these stents will have superior safety and efficacy outcomes compared with the already much improved rates of revascularization and stent thrombosis seen with newer generation stents (everolimus-eluting stents and resolute zotarolimus-eluting stents).<\/jats:p>","DOI":"10.2217\/cer.12.64","type":"journal-article","created":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T16:50:34Z","timestamp":1353689434000},"page":"501-508","source":"Crossref","is-referenced-by-count":0,"title":["Drug-eluting versus bare-metal coronary stents: where are we now?"],"prefix":"10.57264","volume":"1","author":[{"given":"Nicholas S","family":"Amoroso","sequence":"first","affiliation":[{"name":"Cardiovascular Clinical Research Center, The Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[{"name":"Cardiovascular Clinical Research Center, The Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY 10016, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_2_3_1_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJMra051091","volume":"354","author":"Serruys","year":"2006","unstructured":"Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. N. Eng. J. Med. 354(5), 483\u2013495 (2006).","journal-title":"N. Eng. J. Med."},{"key":"e_1_3_2_3_2_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","volume":"331","author":"Serruys","year":"1994","unstructured":"Serruys PW, De Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Eng. J. Med. 331(8), 489\u2013495 (1994).","journal-title":"N. Eng. J. Med."},{"key":"e_1_3_2_3_3_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","volume":"352","year":"1998","unstructured":"EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade. Lancet 352(9122), 87\u201392 (1998).","journal-title":"Lancet"},{"key":"e_1_3_2_3_4_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/heart.84.5.522","volume":"84","author":"Fluck","year":"2000","unstructured":"Fluck DS, Chenu P, Mills P et al. Is provisional stenting the effective option? The WIDEST study (Wiktor stent in de novo stenosis). Widest Trial Investigators\u2019 Group. Heart 84(5), 522\u2013528 (2000).","journal-title":"Heart"},{"key":"e_1_3_2_3_5_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(97)11128-X","volume":"352","author":"Serruys","year":"1998","unstructured":"Serruys PW, Van Hout B, Bonnier H et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 352(9129), 673\u2013681 (1998).","journal-title":"Lancet"},{"key":"e_1_3_2_3_6_2","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jacc.2007.06.029","volume":"50","author":"Morice","year":"2007","unstructured":"Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J. Am. Coll. Cardiol. 50(14), 1299\u20131304 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_3_7_2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jacc.2009.01.050","volume":"53","author":"Weisz","year":"2009","unstructured":"Weisz G, Leon MB, Holmes DR Jr et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. J. Am. Coll. Cardiol. 53(17), 1488\u20131497 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_3_8_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa032441","volume":"350","author":"Stone","year":"2004","unstructured":"Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Eng. J. Med. 350(3), 221\u2013231 (2004).","journal-title":"N. Eng. J. Med."},{"key":"e_1_3_2_3_9_2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.294.10.1215","volume":"294","author":"Stone","year":"2005","unstructured":"Stone GW, Ellis SG, Cannon L et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294(10), 1215\u20131223 (2005).","journal-title":"JAMA"},{"key":"e_1_3_2_3_10_2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa067722","volume":"356","author":"Lagerqvist","year":"2007","unstructured":"Lagerqvist B, James SK, Stenestrand U, Lindb\u00e4ck J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Eng. J. Med. 356(10), 1009\u20131019 (2007).","journal-title":"N. Eng. J. Med."},{"key":"e_1_3_2_3_11_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1540-8183.2007.00312.x","volume":"20","author":"Popma","year":"2007","unstructured":"Popma JJ, Weiner B, Cowley MJ, Simonton C, Mccormick D, Feldman T. FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations. J. Interv. Cardiol. 20(6), 425\u2013446 (2007).","journal-title":"J. Interv. Cardiol."},{"key":"e_1_3_2_3_12_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","volume":"356","author":"Mauri","year":"2007","unstructured":"Mauri L, Hsieh W-H, Massaro JM, Ho KKL, D\u2019agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Eng. J. Med. 356(10), 1020\u20131029 (2007).","journal-title":"N. Eng. J. Med."},{"key":"e_1_3_2_3_13_2","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","volume":"125","author":"Bangalore","year":"2012","unstructured":"Bangalore S, Kumar S, Fusaro M et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117762 patient-years of follow-up from randomized trials. Circulation 125(23), 2873\u20132891 (2012).","journal-title":"Circulation"},{"key":"e_1_3_2_3_14_2","doi-asserted-by":"crossref","first-page":"e5170","DOI":"10.1136\/bmj.e5170","volume":"345","author":"Bangalore","year":"2012","unstructured":"Bangalore S, Kumar S, Fusaro M et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22844 patient years of follow-up from randomised trials. BMJ 345, e5170 (2012).","journal-title":"BMJ"},{"key":"e_1_3_2_3_15_2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"Roger","year":"2011","unstructured":"Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics \u20132011 update. Circulation 123(4), e18\u2013e209 (2011).","journal-title":"Circulation"},{"key":"e_1_3_2_3_16_2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa062598","volume":"355","author":"Laarman","year":"2006","unstructured":"Laarman GJ, Suttorp MJ, Dirksen MT et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N. Eng. J. Med. 355(11), 1105\u20131113 (2006).","journal-title":"N. Eng. J. Med."},{"key":"e_1_3_2_3_17_2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.amjcard.2006.11.070","volume":"99","author":"Daemen","year":"2007","unstructured":"Daemen J, Tanimoto S, Garcia-Garcia HM et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am. J. Cardiol. 99(8), 1027\u20131032 (2007).","journal-title":"Am. J. Cardiol."},{"key":"e_1_3_2_3_18_2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","volume":"120","author":"Kushner","year":"2009","unstructured":"Kushner FG, Hand M, Smith SC Jr et al. 2009 Focused updates: ACC\/AHA Guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC\/AHA\/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 120(22), 2271\u20132306 (2009).","journal-title":"Circulation"},{"key":"e_1_3_2_3_19_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jcin.2008.03.011","volume":"1","author":"Shishehbor","year":"2008","unstructured":"Shishehbor MH, Amini R, Oliveria LP et al. Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. JACC Cardiovasc. Interv. 1(3), 227\u2013232 (2008).","journal-title":"JACC Cardiovasc. Interv."},{"key":"e_1_3_2_3_20_2","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","volume":"377","author":"Stone","year":"2011","unstructured":"Stone GW, Witzenbichler B, Guagliumi G et al. Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 377(9784), 2193\u20132204 (2011).","journal-title":"Lancet"},{"key":"e_1_3_2_3_21_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/archinternmed.2012.758","volume":"172","author":"De Luca","year":"2012","unstructured":"De Luca G, Dirksen MT, Spaulding C et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch. Intern. Med. 172(8), 611\u2013621 (2012).","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_2_3_22_2","unstructured":"Sabate\n\t\t\t\t\t\t M. The EXAMINATION (a clinical evaluation of Xience-V stent in acute myocardial infarction) trial. Presented at: European Society of Cardiology Congress . Paris France 27\u201331 August 2011."},{"key":"e_1_3_2_3_23_2","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","volume":"58","author":"Levine","year":"2011","unstructured":"Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58(24), e44\u2013e122 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_3_24_2","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.amjcard.2006.06.026","volume":"98","author":"Feldman","year":"2006","unstructured":"Feldman DN, Gade CL, Slotwiner AJ et al. Comparison of outcomes of percutaneous coronary interventions in patients of three age groups (<60, 60 to 80, and >80 years) (from the New York State Angioplasty Registry). Am. J. Cardiol. 98(10), 1334\u20131339 (2006).","journal-title":"Am. J. Cardiol."},{"key":"e_1_3_2_3_25_2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Eng. J. Med. 356(15), 1503\u20131516 (2007).","journal-title":"N. Eng. J. Med."},{"key":"e_1_3_2_3_26_2","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","volume":"360","author":"Frye","year":"2009","unstructured":"Frye RL, August P, Brooks MM et al. A randomized trial of therapies for Type 2 diabetes and coronary artery disease. N. Eng. J. Med. 360(24), 2503\u20132515 (2009).","journal-title":"N. Eng. J. Med."},{"key":"e_1_3_2_3_27_2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/CIRCINTERVENTIONS.112.970954","volume":"5","author":"Pursnani","year":"2012","unstructured":"Pursnani S, Korley F, Gopaul R et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ. Cardiovasc. Interv. 5(4), 476\u2013490 (2012).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"e_1_3_2_3_28_2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","volume":"27","author":"Fox","year":"2006","unstructured":"Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 27(11), 1341\u20131381 (2006).","journal-title":"Eur. Heart J."},{"key":"e_1_3_2_3_29_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-5922.2010.00155.x","volume":"29","author":"Kim","year":"2011","unstructured":"Kim MS, Dean LS. In-stent restenosis. Cardiovasc. Ther. 29(3), 190\u2013198 (2011).","journal-title":"Cardiovasc. Ther."},{"key":"e_1_3_2_3_30_2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.ahj.2005.08.011","volume":"151","author":"Chen","year":"2006","unstructured":"Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am. Heart J. 151(6), 1260\u20131264 (2006).","journal-title":"Am. Heart J."},{"key":"e_1_3_2_3_31_2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijcard.2007.06.024","volume":"128","author":"Bainey","year":"2008","unstructured":"Bainey KR, Norris CM, Graham MM, Ghali WA, Knudtson ML, Welsh RC. Clinical in-stent restenosis with bare metal stents: is it truly a benign phenomenon? Int. J. Cardiol. 128(3), 378\u2013382 (2008).","journal-title":"Int. J. Cardiol."},{"key":"e_1_3_2_3_32_2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jacc.2012.01.015","volume":"59","author":"Rittger","year":"2012","unstructured":"Rittger H, Brachmann J, Sinha AM et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J. Am. Coll. Cardiol. 59(15), 1377\u20131382 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_3_33_2","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.jacc.2010.07.028","volume":"56","author":"Dangas","year":"2010","unstructured":"Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J. Am. Coll. Cardiol. 56(23), 1897\u20131907 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_3_34_2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jacc.2004.09.079","volume":"45","author":"Ong","year":"2005","unstructured":"Ong AT, Hoye A, Aoki J et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J. Am. Coll. Cardiol. 45(6), 947\u2013953 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_3_35_2","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","volume":"293","author":"Iakovou","year":"2005","unstructured":"Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126\u20132130 (2005).","journal-title":"JAMA"},{"key":"e_1_3_2_3_36_2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2010.07.038","volume":"160","author":"Mauri","year":"2010","unstructured":"Mauri L, Kereiakes DJ, Normand SL et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am. Heart J. 160(6), 1035\u20131041 (2010).","journal-title":"Am. Heart J."},{"key":"e_1_3_2_3_37_2","author":"Mauri","year":"2011","unstructured":"Mauri L. DAPT duration: review of completed trials & insights from the DAPT trial enrollment. Transcatheter Cardiovascular Therapeutics (2011).","journal-title":"Transcatheter Cardiovascular Therapeutics"},{"key":"e_1_3_2_3_38_2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/CIRCULATIONAHA.111.045229","volume":"124","author":"Yeh","year":"2011","unstructured":"Yeh RW, Normand SL, Wolf RE et al. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. Circulation 124(14), 1557\u20131564 (2011).","journal-title":"Circulation"},{"key":"e_1_3_2_3_39_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0140-6736(05)67221-2","volume":"366","author":"Kaiser","year":"2005","unstructured":"Kaiser C, Brunner-La Rocca HP, Buser PT et al. Incremental cost\u2013effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366(9489), 921\u2013929 (2005).","journal-title":"Lancet"},{"key":"e_1_3_2_3_40_2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1161\/CIRCULATIONAHA.105.546010","volume":"114","author":"Ryan","year":"2006","unstructured":"Ryan J, Cohen DJ. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation 114(16), 1736\u20131743 (2006).","journal-title":"Circulation"},{"key":"e_1_3_2_3_41_2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jcin.2009.10.011","volume":"2","author":"Eisenstein","year":"2009","unstructured":"Eisenstein EL, Wijns W, Fajadet J et al. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De novo Native Coronary Artery Lesions). JACC Cardiovasc. Interv. 2(12), 1178\u20131187 (2009).","journal-title":"JACC Cardiovasc. Interv."},{"key":"e_1_3_2_3_42_2","first-page":"1145","volume":"172","author":"Amin","year":"2012","unstructured":"Amin AP, Spertus JA, Cohen DJ et al. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch. Intern. Med. 172(15), 1145\u20131152 (2012).","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_2_3_43_2","doi-asserted-by":"crossref","first-page":"A195.E1830","DOI":"10.1016\/S0735-1097(10)61831-1","volume":"55","author":"Bangalore","year":"2010","unstructured":"Bangalore S, Selzer F, Williams DO, Faxon DP. Stainless steel versus non-stainless steel stents for percutaneous coronary intervention using bare metal stents: findings from the NHLBI PCI Dynamic Registry. J. Am. Coll. Cardiol. 55(10s1), A195.E1830\u2013A195.E1830 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_3_44_2","doi-asserted-by":"crossref","first-page":"A195.E1829","DOI":"10.1016\/S0735-1097(10)61830-X","volume":"55","author":"Bangalore","year":"2010","unstructured":"Bangalore S, Selzer F, Srinivas VS, Williams DO, Faxon DP. Thin versus thick strut stent for percutaneous coronary intervention using bare metal stents: insights from the NHLBI PCI Dynamic Registry. J. Am. Coll. Cardiol. 55(10s1), A195.E1829\u2013A195.E1829 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_2_3_45_2","author":"King","year":"2012","unstructured":"King L, Byrne RA, Mehilli J, Schomig A, Kastrati A, Pache J. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. Catheter. Cardiovasc. Interv. doi:10.1002\/ccd.24375 (2012) (Epub ahead of print).","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"e_1_3_2_3_46_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(09)60325-1","volume":"373","author":"Serruys","year":"2009","unstructured":"Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667), 897\u2013910 (2009).","journal-title":"Lancet"},{"key":"e_1_3_2_3_47_2","doi-asserted-by":"crossref","first-page":"F36","DOI":"10.4244\/EIJV5IFA6","volume":"5","author":"Waksman","year":"2009","unstructured":"Waksman R, Pakala R. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent. EuroIntervention 5(Suppl. F), F36\u2013F42 (2009).","journal-title":"EuroIntervention"},{"key":"e_1_3_2_3_48_2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"Stefanini","year":"2012","unstructured":"Stefanini GG, Byrne RA, Serruys PW et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur. Heart J. 33(10), 1214\u20131222 (2012).","journal-title":"Eur. Heart J."},{"key":"e_1_3_2_3_49_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jama.2012.10065","volume":"308","author":"Raber","year":"2012","unstructured":"Raber L, Kelbaek H, Ostoijc M et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 308(8), 777\u2013787 (2012).","journal-title":"JAMA"},{"key":"e_1_3_2_3_50_2","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","volume":"123","author":"Kolandaivelu","year":"2011","unstructured":"Kolandaivelu K, Swaminathan R, Gibson WJ et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123(13), 1400\u20131409 (2011).","journal-title":"Circulation"},{"key":"e_1_3_2_4_2_2","unstructured":"Results still mixed in bare-metal versus drug-eluting stent debate. The Journal of Invasive Cardiology website 16 March 2010. www.invasivecardiology.com\/Results-Still-Mixed-Bare-Metal-Versus-Drug-Eluting-Stent-Debate (Accessed 16 September 2012)"},{"key":"e_1_3_2_4_3_2","unstructured":"National Center for Health Statistics. Health United States 2009: in brief-medical technology (2010). www.cdc.gov\/nchs\/data\/hus\/hus09_InBrief_MedicalTech.pdf (Accessed 16 September 2012)"},{"key":"e_1_3_2_4_4_2","unstructured":"Balloon elution and late loss optimization (BELLO) study: a multicentre randomized study of the IN.PACT Falcon paclitaxel drug-eluting balloon to reduce restenosis in small coronary vessels (2012). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01086579?term=bello&rank=1 (Accessed 16 September 2012)"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer.12.64","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:11:46Z","timestamp":1679231506000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer.12.64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.2217\/cer.12.64"],"URL":"https:\/\/doi.org\/10.2217\/cer.12.64","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}